The long-term oncologic outcomes of robot-assisted bronchial single sleeve lobectomy for 104 consecutive patients with centrally located non-small cell lung cancer
Articolo
Data di Pubblicazione:
2022
Citazione:
The long-term oncologic outcomes of robot-assisted bronchial single sleeve lobectomy for 104 consecutive patients with centrally located non-small cell lung cancer / Liu, A.; Zhao, Y.; Qiu, T.; Xuan, Y.; Qin, Y.; Sun, X.; Xu, R.; Du, W.; Wu, Z.; Veronesi, G.; Amore, D.; Jiao, W.. - In: TRANSLATIONAL LUNG CANCER RESEARCH. - ISSN 2218-6751. - 11:5(2022), pp. 869-879. [10.21037/tlcr-22-298]
Abstract:
Background: Up to now, no study has described the long-term survival and its prognostic factors of robot-assisted sleeve lobectomy. Here, the present cohort study reported the long-term oncologic outcomes of robot-assisted sleeve lobectomy to evaluate the oncological feasibility of sleeve lobectomy via a robotic surgical system in patients with centrally located non-small cell lung cancer (NSCLC). Methods: A total of 104 consecutive patients with centrally located NSCLC who underwent robot-assisted bronchial single sleeve lobectomy between October 2014 and May 2021 were retrospectively reviewed. Bronchial single sleeve lobectomy only refers to the resection and end-to-end anastomosis reconstruction of the bronchus, without the resection of the pulmonary vessels or carina. The recurrence status during followup, 5-year overall survival (OS) and disease-free survival (DFS) were assessed. Results: In the total cohort, 47 (45.2%) patients had pathological stage I disease, 28 (26.9%) patients had pathological stage II disease, and 29 (27.9%) patients had pathological stage III disease. Recurrence occurred in 26 (25.0%) patients, including locoregional recurrence in 10 (9.6%) patients and distant recurrence in 16 (15.4%) patients. No endobronchial nor perianastomotic recurrence was detected. The Kaplan-Meier curves indicated that the 5-year DFS and OS rates in the cohort were 67.9% and 73.0%, respectively. In terms of pathological stages, the 5-year DFS and OS rates were 82.9% and 82.2% for stage I patients, 57.8% and 69.7% for stage II patients, and 54.5% and 63.7% for stage III patients, respectively. Multivariable analyses demonstrated that higher pathological stage or N2 stage were independent risk factors for poorer DFS and OS. Conclusions: Robot-assisted bronchial single sleeve lobectomy could be an oncologically adequate procedure for patients with centrally located NSCLC, due to the long-term survival was similar to that reported for video-assisted thoracoscopic surgery (VATS) or open technique. Further studies of comparative studies or high-quality randomized controlled trials are required.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Non-small cell lung cancer (NSCLC); robotic-assisted thoracoscopic surgery (RATS); sleeve lobectomy
Elenco autori:
Liu, A.; Zhao, Y.; Qiu, T.; Xuan, Y.; Qin, Y.; Sun, X.; Xu, R.; Du, W.; Wu, Z.; Veronesi, G.; Amore, D.; Jiao, W.
Link alla scheda completa:
Pubblicato in: